Why Retatrutide Could Be a Game-Changer Retatrutide isnt just another weight loss trend its backed by impressive results and innovative science
AOD-9604 was created to be: Safe Non-habit forming Non-stimulating Suitable for long-term metabolic support Cycling contradicts its original design
Member-Exclusive Pricing JumpstartMD members pay just $79/month
Journal of Neuro-Oncology, 111 (3), 245255
Clinical Trial Evidence for Wegovy Wegovy approval was supported by large, randomized clinical trials, including the STEP 1 study: 1,961 adults with obesity or overweight plus weight-related health conditions 68-week study duration Average weight loss of approximately 14.9% of body weight 86% of participants lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Participants followed reduced-calorie diets and increased physical activity Before receiving FDA approval, GLP-1 medications completed Phase I, Phase II, and Phase III trials
Menstrual changes or vaginal bleeding are not currently listed